Skip to main content

Table 2 Characteristics at follow-up of 273 patients included in the studya

From: Dysglycemia associations with adipose tissue among HIV-infected patients after 2 years of antiretroviral therapy in Mwanza: a follow-up cross-sectional study

Age at follow-up, year

41.5 (9.8) (Range 21–75)

Religion

 Christian

225 (82.4)

 Muslim

34 (12.5)

 No religion

14 (5.1)

Smoking status, n (%)

 Never

197 (72.2)

 Past

65 (23.8)

 Current

11 (4.0)

Alcohol drinking, n (%)b

 Never

108 (39.7)

 Past

133 (48.9)

 Current

31 (11.4)

Fruits and vegetables consumption per day, n (%)

 1–2 servings

81 (29.7)

 3–4 servings

79 (28.9)

  ≥ 5 servings

113 (41.4)

Time spent in vigorous physical activity per week (minutes), n (%)

 Inadequate (<75 min)

64 (23.4)

 Adequate (≥75 min)

209 (76.6)

Weight (kg)

52.8 (8.5)

Body mass index (kg/m2)

19.9 (2.8)

Nutritional status according to BMI categories, n (%)

 Undernourished (BMI < 18.50 kg/m2)

73 (26.7)

 Normal weight (BMI 18.50–24.99 kg/m2)

188 (68.9)

 Overweight (BMI 25.00–29.99 kg/m2)

10 (3.7)

 Obese (BMI ≥ 30.00 kg/m2)

2 (0.7)

Fat mass index (kg/m2)c

4.3 (2.4)

Fat-free mass index (kg/m2)c

15.5 (1.6)

Current antiretroviral therapy regimen, n (%)d

 AZT + 3TC + EFV

41 (15.8)

 AZT + 3TC + NVP

84 (32.3)

 TDF + FTC + EFV

70 (26.9)

 TDF + 3TC + EFV

65 (25.0)

Pre-diabetes, n (%)e

57 (20.8)

Diabetes Mellitus, n (%)

4 (1.5)

Pre-diabetes (IFG + IGT) and Diabetes Mellitus, n (%)

61 (22.3)

  1. AZT Zidovudine, 3TC Lamivudine, EFV Efavirenz, NVP Nevirapine, TDF Tenofovir, FTC Emtricitabine
  2. aData in mean(sd) or n (%)
  3. b272 patients included in analysis
  4. c269 patients included in analysis
  5. d260 patients included in analysis
  6. eImpaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)